Brief: Who Grants Inns For Kancera's Candidate Drugs Kand567 And Kand145
16/06/2025 07:45
June 16 (Reuters) - Kancera AB KANC.ST: WHO GRANTS INNS FOR KANCERA'S CANDIDATE DRUGS KAND567 AND KAND145 WHO GRANTS RUGOCRIXAN AND FOSRUGOCRIXAN AS INNS Source text: ID:nMFN5cG8mM Further company coverage: KANC.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing